In a study of patients who had ever been diagnosed with kidney cancer, those who reported exercise or physical activity in the past 30 days had reduced likelihood of reporting worse physical and mental health.
CBM588, a live bacterial product, improves the efficacy of first-line treatment with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma, a study suggests.
Vegzelma is a vascular endothelial growth factor inhibitor.
The CheckMate -914 trial included patients with localized RCC who underwent radical or partial nephrectomy and who were at high risk of relapse.
The investigational product targets CD70, which is highly expressed in renal cell carcinoma with limited normal tissue expression.
HLA-A*03 was associated with worse progression-free and overall survival.
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma.
The sBLA submissions are supported by data from the phase 3 KEYNOTE-564 trial and the phase 2 KEYNOTE-158 trial.
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
